Antitoxin and vaccine platform based on nodavirus VLPS
AssigneesThe Salk Institute for Biological Studies, The Scripps Research Institute
InventorsJohn Young, Anette Schneemann, Marianne Manchester, Kelly Dryden, John M. Marlett, Darly Joseph Manayani, Godfrey Jonah Anderson Rainey, Vijay Reddy, Marc E. Siladi, Heather M. Scobie, Diane Thomas, Mark Yeager
Life of this patent
Estimating the term…
Abstract
Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.
Claims11
An immunogenic composition comprising a nodavirus-derived virus like particle (VLP) that comprises a heterologous immunogen binding domain, said heterologous binding domain comprising an anthrax binding sequence of an extracellular von Willebrand factor A (VWA) domain, which binding domain is bound to a first heterologous immunogen, wherein the heterologous immunogen comprises a first domain and a second domain, wherein the first domain comprises an anthrax protective antigen and the second domain comprises a botulinum antigen.
An immunogenic composition comprising a nodavirus-derived virus like particle (VLP) derived from Flock House Virus, said VLP comprising a heterologous immunogen binding domain, said binding domain being bound to a first heterologous immunogen, said heterologous immunogen comprising a first anthrax protective antigen domain coupled to a second heterologous domain comprising a botulinum toxin.
An immunogenic composition comprising a first and second nodavirus-derived virus like particle (VLP) wherein the first VLP is different from the second VLP, wherein the first and second VLPs each comprise a VWA domain of capillary morphogenesis protein 2 (ANTRX2) bound to a respective first and second heterologous immunogen, further wherein the first and second heterologous immunogen each comprise a fusion protein, said fusion protein comprising a first domain derived from anthrax protective antigen and a second domain selected from a ricin toxin antigen, botulinum toxin antigen, or other immunogen of interest, wherein the second domain of the first and second heterologous immunogens are different.
Dependencies are inferred from the claim text.